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Abstract  
Context: Long term survival following a diagnosis of cancer is improving in developed nations. 
However, living longer, does not necessarily equate to living well. 
 
Objective: Systematically search and narratively synthesise the evidence from randomised controlled 
trials of supportive interventions designed to improve prostate cancer specific quality of life. 
 
Evidence Acquisition: A systematic search of MEDLINE and EMBASE was carried out from inception 
to July 2014 to identify interventions targeting prostate cancer quality of life outcomes. We did not 
include non-randomised studies or trials of mixed cancer groups. In addition to database searches, 
citations from included papers were hand searched for any potentially eligible trials. 
 
Evidence synthesis: A total of 2654 prostate cancer survivors from 20 eligible randomised controlled 
trials were identified from our database searches and reference checks. Disease specific quality of 
life was assessed most frequently by the functional assessment of cancer therapy-prostate 
questionnaire. Included studies involved men across all stages of disease. Supportive interventions 
that featured individually tailored approaches and supportive interaction with dedicated staff 
produced the most convincing evidence of a benefit for prostate cancer specific quality of life. Much 
of these data come from lifestyle interventions. Our review found little supportive evidence for 
simple literature provision (either in booklets or via online platforms) or cognitive behavioural 
approaches. 
 
Conclusions: Physical and psychological health problems can have a serious negative impact on 
quality of life in prostate cancer survivors. Individually tailored supportive interventions such as 
exercise prescription/referral should be considered by multi-disciplinary clinical teams, where 
available. Cost-effectiveness data and an understanding of how to sustain benefits over the long 
term are important areas for future research. 
 
Patient summary: This review of supportive interventions for improving quality of life in prostate 
cancer survivors found that supervised and individually tailored patient centred interventions such 
as lifestyle programmes are of benefit.  
 
 
 
1.           Cancer survivorship in context 
Long term survival following a diagnosis of cancer is improving in developed nations.[1] The term 
‘cancer survivor’ is an umbrella term describing the broad experience of the cancer continuum, i.e.  
“living with, through, and beyond a cancer diagnosis.” This definition has been proposed by the 
National Consortium for Cancer Survivorship in the USA and is echoed by European cancer charities 
such as Macmillan.  The term has evolved and disseminated into clinical practice following high 
profile advocates such as Dr Fitzhugh Mullan, describing his own cancer journey from a clinician's 
perspective in the New England Journal of Medicine, nearly 30 years ago.[2] 
 
Living longer however, does not necessarily equate to living well. Acceptance that cancer and its 
treatments can have a negative long term effect on quality of life has been increasing over the past 
40 years. This was first evidenced by the passage of the National Cancer Act in the USA (1971) which 
promoted research into meeting ongoing post-diagnosis needs. By the early 1980s new initiatives 
such as dedicated rehabilitation programmes directed at improving quality of life began to 
emerge.[3] Hence, within the survivorship agenda is an implicit undertaking to improve quality of life  
in those diagnosed and treated for cancer. Whereas the concept of ‘quality of life’ is intuitive, it is 
generally a personal construct and has traditionally been difficult to measure. Reliable measurement 
and comparison have been improved by the development and validation of generic health related 
quality of life tools (e.g. short-form 36, EUROQoL EQ-5D), instruments to measure quality of life 
across cancer in general (e.g. EORTC QLQ-C30) cancer-related fatigue (e.g. FACT-F), and disease-
specific tools (e.g. FACT-P, EORTC Prostate-specific tool QLQ-PR25 for prostate cancer ). A review of 
tools to measure quality of life in prostate cancer survivors is freely available on the web.[4] 
 
The organisation of medical care in Europe has typically not been as quick to adopt such paradigms 
in standard health care. For example, the UK  government only recognised a lack of focus on the long 
term consequences of a cancer in its ‘Improving outcomes’ strategy document in 2010.[5] In 
recognition of this, the National Cancer Survivorship Initiative was launched, recommending that  
cancer be considered as analogous to living with a long-term or chronic condition.[6]  Prostate 
cancer, in particular, fits this long-term condition paradigm: it is the main global contributor to years 
lived with cancer disability [7] with an estimated global prevalence of around four million men in 
2012.[8]   
 
All clinicians treating men with prostate cancer, regardless of stage, need to be aware of the issues 
that affect quality of life in men with prostate cancer - both immediately after diagnosis and 
treatment and in the many years that follow. The relevance to a urological audience is that the 
urologist is often the primary (and indeed may be the only) treating physician, nevertheless, high-
quality survivorship requires engagement from all involved in the care of men with prostate cancer. 
The aim of this manuscript is to 1) contextualise living with and beyond prostate cancer with 
particular regard to adverse events associated with treatment 2) review the effects of interventions 
that can improve prostate cancer specific quality of life and 3) highlight how care co-ordination and 
symptom management can be addressed by multi-disciplinary teams.  
 
2.           The lived experience of prostate cancer 
People surviving cancer are less likely to report favourable quality of life than individuals from the 
general population or patients surveyed from primary care.[9] Further, cancer survivors are 
significantly more likely to report being in average or poor general health (47% of survivors vs 17% of 
healthy participants).[10] Nearly half with common cancers (breast, bowel, prostate) will suffer from 
additional chronic conditions: most frequently these are arthritis, heart disease, diabetes, asthma 
and osteoporosis.[10] Indeed, data from the Surveillance, Epidemiology and End Results Tumour 
Registry (103,086 men aged 66 to 84 diagnosed with prostate cancer), reported roughly equivalent 
rates of prostate cancer (7.7%) and cardiovascular (7.2%) mortality.[11] At the population-level, risk 
of prostate cancer death is predicated upon numerous factors including the prevalence of PSA 
screening. Advancing age, co-morbidity and adverse effects of treatment for advanced disease are 
likely key determinants of non-cancer mortality.  
 
From a psychological perspective, data from a meta-analysis indicate clinically relevant depression to 
be present in 17%, 15% and 18% of men before, during and after treatment for prostate cancer, 
respectively. Similarly, clinically relevant anxiety is high with a pre-treatment, on-treatment and 
post-treatment prevalence reported at 27%, 15%  and 18%, respectively.[12] In advancing disease 
where medical or surgical castration is utilised, the risk of incident psychiatric illness (composite of 
depression, dementia, anxiety, insomnia, psychosis) is up to 26% over a seven year follow-up. [13] It 
is important to note that suicidal intent in prostate cancer survivors is associated with both physical 
and psychological dysfunction.[14] Hence, clinicians should be aware that as many as one in four of 
their patients could have clinically relevant psychological morbidity.  
 
Without consideration of these data by the clinician responsible for primary treatment, it is easy to 
conceive that these issues would go unidentified and a number of men have to endure untreated 
psychological distress.[15] These data underscore the importance of symptom recognition by the 
primary treating clinician. 
 
3.      Adverse effects of anti-cancer treatment   
 
3.1 Radical therapies 
The adverse effects of surgery in the form of radical prostatectomy (RP) can be broadly categorized 
as complications related to function (e.g. continence, erectile) or others (e.g. anastomotic leak). 
Reported post-RP urinary incontinence rates range from 5 to 72%.[16] Factors including older age, 
higher body mass index, increasing comorbidity index, preoperative lower urinary tract symptoms, 
greater prostate volume, and the postoperative development of an anastomotic stricture have been 
associated with an increased risk for persistent incontinence.[16-18]  Rates of erectile dysfunction 
after RP range from 31 to 86%, [16] depending on the definition of potency, the population studied, 
and the timeframe evaluated.  Factors associated with postoperative erectile function include age, 
preoperative erectile function, comorbidity status, body mass index, pre-treatment PSA, the extent 
of nerve-sparing performed at surgery. [16, 19, 20]  
 
Importantly, non-functional complications from RP may arise both in the perioperative period as 
well as during extended follow-up after surgery.  Indeed, critical analysis of RP series have 
collectively found the procedure to be associated with an overall complication rate of approximately 
10%, although the vast majority of complications are low-grade, most commonly lymphocele/ 
lymphorrhea and urine leak.[21]  Comorbidity status, extent of disease and surgical approach have 
been variously associated with perioperative outcomes. Surgeon experience may also be related to 
complication rates.[21]   
 
Prostatic irradiation (RT) is most commonly associated with adverse effects around late rectal 
function/ toxicity (i.e. increased frequency and urgency of defecation, faecal incontinence and rectal 
bleeding).[22] High dose RT to the rectal wall can lead to anatomical and functional damage 
including telangectasia, mucosal congestion, ulceration and fibrosis [23] with associated impairment 
of sensation, compliance and capacity. [24] Similarly, irradiation of the anal sphincter complex may 
impair function. As such, compared to RP, RT is more likely to induce declines in bowel function at 
two, five and 15 years of follow-up.[25] A recent critical review of functional outcomes reports that 
total urinary incontinence and other severe urinary symptoms are rare.[26] However, bothersome 
storage urinary symptoms are relatively common among patients undergoing radiation therapy, and 
some men may also experience fatigue and erectile dysfunction. 
 
3.2 Androgen deprivation therapy 
Despite its acknowledged anti-cancer benefits [27-29], androgen deprivation therapy (ADT) is 
associated with a range of adverse effects in survivors. These have been extensively covered in a 
recent review in European Urology.[30] Briefly, these include increased fracture risk,[31] metabolic 
consequences and cardiovascular events,[32-36] genital and sexual dysfunction,[37, 38] fatigue [39] 
and anaemia.[40] The association between ADT and cardiovascular risk remains controversial and 
this has been discussed elsewhere.[33, 36, 41] 
 
4.           Evidence acquisition 
A systematic search of the electronic databases MEDLINE (via PubMed) and EMBASE was carried out 
from inception to July 2014 to identify interventions targeting prostate cancer quality of life 
outcomes. MEDLINE search terms were prostate cancer [TIAB] AND (quality of life [TIAB]) using a 
randomised controlled trial (RCT) only filter.  EMBASE search terms were prostate cancer AND 
quality of life using an RCT only filter. Eligible studies that are known to the authors but not picked 
up by the data base searches, were also evaluated for inclusion. We only included supportive 
interventions that were directed at improving a prostate cancer specific quality of life outcome in 
men with diagnosed prostate cancer evaluated in an RCT with a usual care comparison.  We did not 
include non-randomised studies or trials of mixed cancer groups. In addition to database searches, 
citations for included papers were hand searched for any potentially eligible trials. Quality appraisal 
was done according to prostate cancer trial expertise and clinical judgement of the authors (led by 
LB). Results were screened firstly by title, then abstract and then full text in order to generate a 
PRISMA flow diagram of results.[42] Due to the likely heterogeneity of interventions and the non-
standardised quality appraisal, a narrative synthesis rather than a quantified meta-analysis of data 
was performed. 
 
5.           Search results  
A total of 22 manuscripts from 20 trials were identified through our searches (see Figure 1), involving 
2654 prostate cancer survivors. Quality of life was assessed by questionnaire in all trials, involving 
survivors with T stage 1-4 prostate cancer. Interventions were broadly categorised as lifestyle 
interventions (10 studies), educational support (five studies), enhanced standard care (three studies) 
or cognitive behavioural approaches (two studies). Table 1 provides a summary of included studies.    
 6.          Evidence synthesis 
 
6.1 Lifestyle  
Exercise interventions 
The last decade has seen a growing interest in interventions that improve exercise behaviour and 
have been hypothesized to improve clinical outcomes in men with prostate cancer.  
Early pilot study data (intervention n =11, control n =10) reported that in men receiving radiotherapy 
for localised prostate cancer, a directly supervised (by a kinesiotherapist and physician) aerobic 
exercise training programme, consisting of three sessions of moderate intensity exercise for eight 
weeks, significantly improved FACT-P scores in the intervention group compared to controls. [43]  
Crucially, the mean difference between groups (14 points, SD = 10 points) exceeded the reference 
range which suggests clinically meaningful results (i.e. 6-9 points). [44] These effects were not 
however, substantiated in a later, larger RCT comparing aerobic (n=40) or resistance training (n=40) 
to usual care (n =41) in men scheduled to receive radiotherapy. [45] This is despite the trial reporting 
excellent adherence to the interventions with 88 and 83% of the sessions completed in the 
resistance and aerobic groups, respectively. The conflicting findings of these trials could be explained 
by a number of factors. First, the larger study included a wider, heterogeneous cohort of men with 
diagnosed stage I-IV cancers, with around 60% of the overall cohort on ADT. In addition, nearly half 
of the cohort was already regularly active at baseline, raising the possibility of uncertain incremental 
gains in these individuals from participating in the trial intervention. Another important difference is 
in the utilisation of the FACT-P questionnaire. The early pilot trial administered and reported data 
from a composite of the full FACT-G questionnaire with the additional FACT-P prostate specific sub-
scale to give a more informed overview of quality of life, where the larger RCT reported data from 
the 12 item subscale only.   
 
In one of the first RCTs of an exercise intervention involving men with prostate cancer, Segal and 
colleagues [46] randomised men with stage I-IV disease scheduled to receive at least 3 months of 
ADT to a 12 week supervised resistance exercise training programme (n= 82) or a waiting list control 
group (n=73).  Significant differences in FACT-P mean change scores were reported at 12 weeks of 
follow-up (mean +2 points [SD =9 points] vs. - 3 points [SD =10 points] in the intervention and 
controls, respectively). Whilst this does not achieve the suggested clinically relevant threshold, 
planned exploratory analysis suggested that significant effects were present regardless of curative or 
palliative treatment intent, or duration of ADT. Further support for exercise training in men on ADT 
has recently been reported by Cormie and colleagues.[47] Randomising men on ADT for at least two 
months (with at least 6 months planned retention) to either a 12 week supervised aerobic and 
resistance training programme or usual care, produced significant effects on sexual activity as 
measured by the EORTC QLQ-PR25 tool. Whilst this represents a novel and potentially important 
outcome, some caution is warranted due to the limited sample size (exercise n = 29, control n = 27). 
It should also be noted that there was very little improvement in sexual activity in the intervention 
group but rather maintenance of baseline activity over the intervention period, compared to 
controls who reported substantial declines.   
 
Despite some encouraging data from supervised exercise programmes, it is unclear as to whether 
such interventions could be readily incorporated into service provision in secondary care. With this 
in mind, home based interventions have been utilised as an attempt to recreate some of the clinical 
benefits whilst reducing costs and resources associated with supervised programmes. The largest of 
these trials involved men from all disease stages (described as 'local' to 'metastatic') but with the 
majority treated radically.[48] Randomisation was to either a simple two page fact sheet on physical 
activity guidelines for adults (n = 141), self-directed exercise goal setting, barrier identification and 
planning (n = 141) or telephone counselling assisted exercise goal setting, barrier identification and 
planning (n = 141). After three months of follow-up, no effect on prostate cancer specific quality of 
life was reported. Critically, only 13.6% of participants in the intervention groups had reported 
completing the intended goal setting and planning activity, rendering a conclusion of no intervention 
effect as uncertain. It is also salient to note recruited participants were already physically active for 
an average of at least two hours per week at baseline, raising the potential for celling effects this 
trial cohort. Home based approaches in men on ADT have also been attempted with similar null 
effects on quality of life.[49] This trial suffered from a 34% drop out over the 16 week intervention 
period, rendering a high risk of bias around these data.    
 
Diet 
Modifications to dietary behaviours have generated interest in the research community through 
potential beneficial impacts on a wide range of clinically relevant outcomes in prostate cancer from 
disease progression [50] to mitigating the side effects of ADT. [51]  
 
A supervised programme of 11 weekly cooking classes (2.5 hours each) encouraging the preparation 
of plant based meals, fish, soy and avoiding meat and dairy products, reported a significant effect on 
FACT-P in men with biochemical recurrence after radical therapy.[52] It is unfortunately not possible 
to ascertain whether this difference was clinically meaningful in effect size, as no point estimates or 
measures of variation were included in the manuscript. These data should be regarded as 
preliminary only, given the small sample (n=36). Some support for soy supplementation in the diet of 
men on ADT has been reported by Vitolins and colleagues [53] in a trial evaluating soy protein 
supplementation (20 g with 160 mg isoflavones, n = 30), versus Venlafaxine (75mg once daily, n 
=30), versus combined soy and Venlafaxine (n =30) or milk powder placebo (n =30). The authors 
reported a significant and clinically relevant difference in FACT-P after 12 weeks in men taking soy 
protein (mean = 113 points, SE = 6 points) versus men who did not take soy protein (mean = 104 
points, SE = 6 points). Whilst this is positive, it should be noted that the analysis presented pooled 
data from both the soy only and soy with Venlafaxine arms. Hence, it is not possible to untangle the 
possible effect(s) of each individual intervention. 
 
Importantly, other elements of dietary change designed to mitigate adverse effects of radical 
treatment, have not produced improvements in quality of life. No significant effect was reported in 
survivors with stage I-III disease [54] scheduled to undergo seven weeks of radiotherapy (in 
combination with either high dose brachytherapy or proton therapy) who were randomised to 
receive advice to reduce lactose consumption and choose foods with soluble fibre (n =64) or 
standard care (n =66). Discrepancies in findings across these three trials could be explained by the 
different primary treatment regimens in these studies, the impact of pharmacological agents in 
combination with diet changes, or could again be a reflection of more intensive intervention delivery 
in the pilot RCT. 
 
Exercise and diet  
Recent data from an evaluation of an individually tailored, combined exercise and dietary advice 
intervention has demonstrated novel improvements in quality of life in men with advanced disease 
on planned long term retention on ADT.[55] Specifically, men were randomised to usual care (n = 50) 
or to receive tapered supervised aerobic and resistance exercise along with dietary advice 
encouraging reduction of saturated fat and refined carbohydrate and increase of dietary fibre intake 
(n = 50). Crucially, all participants were not active at baseline, enhancing the generalisability of these 
data (the large majority of men with prostate cancer are not regularly active).[9] Clinically relevant 
improvements in FACT-P were reported at the end of the intervention at 12 weeks of follow (p = 
0.001, mean difference = 8.9 points). However, these benefits were not sustained at six months  
post-intervention when support was withdrawn, and notably trial retention dropped from 85 to 
68%. These data underscore the importance of sustainability associated with lifestyle-based 
interventions directed towards improvement in prostate cancer specific quality of life.  
 
With the supportive evidence from exercise interventions, combining them with dietary advice 
would appear to be a promising strategy for improving prostate cancer specific quality of life. In 
addition, exercise interventions could positively effect a range of other important patient outcomes. 
A systematic review of this topic is currently underway.[56] To ensure sustainability of the benefits, 
on-going support from dedicated staff and a mix of supervised and independent intervention 
components is required.[57] The treating clinician could play an important role in directly advocating 
such programmes and arranging referral. These interventions are comparatively low risk to 
participants: the major obstacle is likely the cost of physical infrastructure (although this need not be 
based in secondary care, this could be community based) and staff time.  
 
6.2 Educational support interventions 
Given the numerous adverse effects associated with primary treatment for prostate cancer, the 
potential impact of clinical applications of educational support has been evaluated using several 
approaches. 
 
Multi-disciplinary approaches 
Both pilot (n = 57) and larger trial (n =250) results of group based multi-disciplinary interventions 
(facilitated by a health psychologists, medical oncologists, urologists, dieticians and psychiatrists) 
reported small benefits on FACT-P outcome (effect size=0.1) at six  months [58] or no interaction 
effect on the UCLA PCI urinary, bowel or sexual function at 12 months, [59] of follow-up.  Recent 
data from Dieperink and colleagues [60] is more positive. Prostate cancer survivors treated with 
radiotherapy and ADT were assigned to outpatient, mixed nurse and physical therapist led 
counselling (n=79) or usual care (n=82). The nursing component provided psychological support and 
identified disease specific problems for the survivor and their spouse, whilst the physical therapist 
worked to improve pelvic floor muscle function and general physical activity. The urinary irritative 
sum-score and hormonal domains of the EPIC questionnaire significantly improved in the 
intervention vs controls at 20 weeks of follow-up (effect size = 0.34, 0.4 and 0.19, respectively).  This 
intervention likely succeeded where earlier trials have not, by involving a smaller number of health 
professionals and allowing more focused tailoring of the intervention. Such approaches have been 
supported by prostate cancer survivors in qualitative investigation following rehabilitation 
interventions previously. [61] 
 Literature provision and online resources 
Two pilot trials evaluating provision of an educational booklet or referral to an online support group 
suggested a positive beneficial effect in disease specific quality of life. However, authors of the 
booklet evaluation did not report interaction effects or point estimates in their analysis of FACT-P 
scores, choosing to separately analyse pre and post test scores in the intervention and control 
group. [62]  The online support group seemed to initially improve EPIC scores over  six weeks but 
these beneficial effects were transient, returning to baseline just two weeks later. [63]  Hence, there 
is uncertainty around meaningful clinical benefit from these early data.  
 
As with exercise interventions, the individually tailored approach of Dieperink and colleagues offers 
promise for prostate cancer survivors. Further independent observations offering supportive data 
alongside cost effectiveness evidence is now required.  
 
6.3 Enhanced standard care 
Enhancing existing features of prostate cancer care could lead to better outcomes for survivors. For, 
example, men who engage and participate in treatment decision making are considered to 
experience better satisfaction with overall care. To evaluate if this extended to disease specific 
quality of life, Hack and colleagues [64] evaluated the provision of audiotapes of treatment 
consultations with oncologists to men with stage I-IV disease. Men were randomised to no audio 
taping (n = 113), audio taping performed but no tape provided (n =98), audio tape provided (n = 120) 
or tape provided on patient request (n= 94). No effect on quality of life was reported at 12 weeks of 
follow-up. This large RCT suggests there is no clinical benefit of audiotaping treatment consultations.  
 
Pelvic floor muscle training is an important element of post radical prostatectomy rehabilitation. 
Evaluation of enhancing recovery with the aid of a physiotherapist (n=38) compared to standard 
care (n=42) did not result in any disease specific quality of life gains in men with stage I-III 
disease.[65, 66]  However, some potential for type II error must be considered in this trial as only 
50% of intervention participants attended the physiotherapist led group training sessions.  
 
Tailored, nurse-led initiatives have reported more promising data. Giesler and colleagues [67] 
designed an intervention to enhance quality of life using the 'proximal: distal' framework (i.e. 
identification of clinical symptoms with the downstream intention effecting life satisfaction). 
Prostate cancer specific issues (e.g. urinary dysfunction, cancer worry, fatigue etc.) were identified 
with matched interventional strategies e.g. Kegel exercises for urinary incontinence. Patient-spouse 
dyads in the intervention arm met once each month for 6 months with a nurse (twice in person and 
4 times by telephone). At 12 months of follow-up, improvement in sexual limitation (P=0.02, effect 
size 0.5) and cancer worry (P=0.03, effect size 0.51) were reported in the intervention group, 
compared to controls. These data add further support to the evidence for tailored interventions 
delivered by dedicated staff to improve prostate cancer specific quality of life.   
 
6.4 Cognitive behavioural approaches 
Two studies have evaluated cognitive behavioural approaches in survivors with localised disease.  
The first, larger trial, [68] randomised men scheduled to undergo radical prostatectomy to individual 
sessions of cognitive behavioural stress management (n=53) with the majority of the 90 minute 
content focused on relaxation skills and guided imagery, supportive attention (n=54) or standard 
care (n = 52).  No effect on UCLA PCI outcomes was reported after up to 12 months of follow-up.  
The later, smaller study (n=60), assessed the potential of a cognitive–behavioural group intervention 
that addressed the psycho-sexual adjustment of men up to five years post radical prostatectomy. 
[69] Disease specific quality of life was evaluated using the prostate cancer quality of life scale. The 
authors indicated the intervention improved sexual confidence, intimacy, masculine self-esteem and 
satisfaction with orgasm in a hierarchical regression. However, it is difficult to understand the clinical 
relevance of this data, as post-intervention means and 95% confidence intervals were presented 
only for the cohort as a whole, rather than according to randomisation. As such, it appears that 
currently, there is little evidence that cognitive behavioural approaches can be recommended in 
clinical practice for improving prostate cancer specific quality of life.  
 
7. Survivorship care coordination and the interface with primary care 
Coordination of care for prostate cancer survivors is essential to optimize quality of life and promote 
efficient health care utilization although no randomized trials currently examine this in prostate 
cancer specifically. However, fragmented, poorly coordinated prostate cancer survivorship care may 
be associated with duplicate services e.g. PSA testing and greater spending, particularly amongst 
those treated with radical therapy.[70] A lack of agreement regarding roles and responsibilities 
among patients, primary and specialty care providers during survivorship can exacerbate the 
issue.[71, 72]  The Institute of Medicine formally recognized the need to address coordination of 
survivorship care nearly a decade ago by recommending provision of a survivorship care plan. This 
includes a treatment summary and follow-up care plan for cancer survivors as they transition across 
the primary/ specialty care interface. This standard will require an institution's cancer committee to 
develop and implement a process for disseminating comprehensive care summaries and follow-up 
plans to cancer patients completing treatment with the hope of improving patient-centred care and 
outcomes. However, the evidence to support formalized cancer survivorship care plan development 
and provision are mixed and concerns remain regarding their implementation (e.g., reimbursement, 
maintenance, contents).[73] According to a recent nationally-representative survey in the USA, 
primary care providers who received a survivorship care plan from an oncologist were nine times 
more likely to report survivorship discussions with cancer survivors. [71] However in the same study, 
less that 5% of oncology providers routinely issued a written survivorship care plan, and survivorship 
care discussions among primary care providers and patients are still rare. 
 
The American Cancer Society Prostate Cancer Survivorship Care Guidelines [74] support the IOM 
recommendations that cancer specialists provide survivorship care plans including treatment 
summary and follow up recommendations to primary care providers. The guidelines also highlight 
some practical shared care recommendations to optimize longitudinal prostate cancer survivorship 
care and quality of life. Firstly, they recommended specialist provision of a post-treatment patient-
reported measure of side effect burden (e.g., the one page Expanded Prostate Cancer Index 
Composite for Clinical Practice) [75] to primary care providers to facilitate longitudinal self- and 
medical management efforts. A second recommendation was a minimum of annual assessment of 
late and long-term health-related quality of life effects including the psychosocial effects of a cancer 
diagnosis.  A third was  inter-professional shared decision-making among the primary and specialty 
care providers to tailor roles and responsibilities for central tenets of survivorship care including  
health promotion, prostate cancer surveillance, screening for second primary cancers, long-term and 
late effects assessment and management based on the patient’s condition and resources/expertise 
in their primary care setting.  The latter is especially important given previous disagreement among 
the primary care and oncology communities regarding survivorship follow up care coordination and 
responsibilities.[76] These guidelines were recently endorsed by the American Society for Clinical 
Oncology with minor modifications. 
 
8. Review limitations 
This manuscript specifically targeted randomized clinical trials addressing prostate cancer quality of 
life outcomes finding several educational, lifestyle, and behavioural interventions that may improve 
disease specific quality of life. Other behavioural, medical and surgical approaches to symptom and 
side effect management are covered elsewhere [74] and were not the focus of this review. 
Nevertheless, more work needs to be done in this field to build the high level evidence base 
necessary to support men, their partners and clinicians as they survive prostate cancer. A lack of 
consistent instrument selection in the included studies makes evidence synthesis challenging with 
respect to which intervention and instrument outcomes are most relevant to individual survivors 
(e.g., urinary, bowel, sexual, psychosocial, merits of exercise, etc.). Consensus on which instruments 
are most informative would likely be an informative next step. The FACT-P tool was the most 
frequently used in the studies included in the present review. A recent international working group 
advocated the Expanded Prostate Cancer Index Composite Short Form for assessing men with 
localised prostate cancer. [77] 
 
9. Research recommendations 
The treating clinician could play a role in directly advocating supportive programmes to survivors 
and leading the multi-disciplinary team in the referral process. Qualitative evaluation of how some 
of the interventions covered in this review could be introduced into standard care (e.g. in the NHS) 
would be an ideal way to identify barriers, facilitators and map roles and responsibilities for care 
teams looking to deliver evidence based survivorship care. Multi-centre, randomised clinical trials of 
such pragmatic complex interventions would appear to the best way of evaluating effectiveness in 
the long term. Crucially, cost effectiveness data have not been generated for these programmes, and 
should be collected in parallel during clinical studies. These data will play an important role in the 
dialogue with commissioners, insurers and other payers.  
 
10.        Conclusions 
Prostate cancer is the main global contributor to years lived with cancer disability. Primary 
treatments can often leave men with serious ongoing health problems, both physical and 
psychological, which adversely affect quality of life. Supportive interventions which incorporate 
direct interaction with specialist health professionals and feature individually tailored prescriptions 
have shown promise for improving disease specific quality of life. Much of the data in this review 
comes from lifestyle interventions. Whilst these data are promising, these programmes are non-
standard for most clinical teams in terms of delivery. As such, further understanding of how these 
programmes can be implemented in current practice and how patient engagement and adherence 
can be maximised, is required. These initiatives are likely to be of low risk in terms of potential harm 
to participants.  
 
 
 
 Figure Legends: 
Table 1: Summary of table of included randomised controlled trials 
Figure 1: PRISMA flow diagram of search results.  
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